Highlights
Adjuvant imatinib treatment was associated with a significant reduction in the early hazard of recurrence or death (HR, 0.19) in patients with KIT exon 9-mutant gastrointestinal stromal tumors (GISTs).
The study demonstrated a clear overall survival (OS) benefit (HR, 0.37) for patients receiving adjuvant imatinib compared to observation alone.
In the high-risk subgroup, no significant difference in efficacy was observed between a standard 400 mg/day dose and a higher 800 mg/day dose, suggesting that the standard dose may be sufficient in the adjuvant setting.
The findings support the routine use of adjuvant imatinib for at least three years in patients with high-risk KIT exon 9-mutant GIST following curative-intent surgery.
Background and Clinical Context
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, primarily driven by activating mutations in the KIT or PDGFRA receptor tyrosine kinases. Among these, KIT exon 9 mutations represent a unique molecular subgroup, accounting for approximately 10% to 15% of cases. These tumors typically arise in the small intestine and exhibit biological behavior distinct from the more common KIT exon 11 mutations.
In the setting of advanced or metastatic disease, KIT exon 9-mutant GISTs are known to be less sensitive to the standard 400 mg daily dose of imatinib. Clinical trials in the metastatic setting, such as the EORTC 62005 and MetaGIST analyses, established that a higher dose of 800 mg daily provides superior progression-free survival for these patients. However, the role and optimal dosing of adjuvant imatinib—treatment administered after complete surgical resection—have remained a subject of debate. Until now, prospective randomized trials evaluating adjuvant imatinib (such as ACOSOG Z9001 and SSG XVIII/AIO) were either underpowered for this specific mutation or did not differentiate dosing strategies for exon 9 variants. Consequently, clinicians have faced uncertainty regarding whether the survival benefits seen in exon 11 patients translate to the exon 9 population, and whether the higher 800 mg dose is necessary in the adjuvant setting.
Study Design and Methodology
To address these uncertainties, researchers conducted an international, multicenter cohort study involving 35 referral centers across Europe, the United States, and Japan, as well as data from the Life Raft Group database. The study cohort included 367 patients with localized, molecularly confirmed KIT exon 9-mutant GISTs who underwent curative-intent surgery between 1990 and 2022.
The primary exposures were adjuvant imatinib versus observation. Recognizing the potential for immortal time bias—where patients must survive long enough to receive treatment—the researchers modeled imatinib as a time-dependent covariate. The primary endpoints were recurrence-free survival (RFS) and overall survival (OS). The researchers utilized multivariable Cox regression models and overlap weighting (OW) based on propensity scores to control for confounding factors such as tumor size, mitotic count, and tumor site. A secondary analysis specifically compared the efficacy of 400 mg/d versus 800 mg/d dosing within the high-risk subgroup as defined by the modified National Institutes of Health (mNIH) criteria.
Key Findings: Survival and Recurrence Outcomes
Of the 367 patients included in the analysis (mean age 56 years; 51% male), 276 (75.2%) received adjuvant imatinib, while 91 (24.8%) were managed with observation. The median duration of imatinib therapy was 27.3 months, with 42% of treated patients receiving the drug for three years or longer.
Recurrence-Free Survival (RFS)
Adjuvant imatinib was associated with a dramatic reduction in the early risk of recurrence. The initial hazard ratio (HR) was 0.19 (95% CI, 0.10-0.36), indicating a substantial protective effect shortly after surgery. However, the study observed an attenuation of this benefit over time (time-interaction HR, 1.85 per log-year), which is consistent with the cytostatic rather than cytotoxic nature of imatinib. This suggests that while imatinib effectively delays recurrence, the risk may rise once the medication is discontinued, emphasizing the importance of treatment duration.
Overall Survival (OS)
Crucially, the study demonstrated that the benefit of adjuvant therapy extended to overall survival. Patients receiving imatinib had a significantly lower risk of death (HR, 0.37; 95% CI, 0.17-0.83) compared to those in the observation group. This finding is particularly significant because it suggests that the delay in recurrence achieved by adjuvant therapy translates into a long-term survival advantage for patients with KIT exon 9 mutations, despite their reduced sensitivity to imatinib in the metastatic setting.
Dosing Considerations: 400 mg vs. 800 mg
One of the most clinically relevant aspects of this study was the comparison of imatinib dosages. Among 257 high-risk patients who received adjuvant treatment, no significant difference in RFS or OS was detected between those receiving the standard 400 mg/day dose and those receiving the higher 800 mg/day dose. This suggests that the increased toxicity often associated with the 800 mg dose may not be necessary to achieve optimal outcomes in the adjuvant setting, a notable departure from the established protocols for advanced disease.
Expert Commentary and Clinical Implications
The results of this study provide the strongest evidence to date supporting the use of adjuvant imatinib in KIT exon 9-mutant GIST. For years, the oncology community has extrapolated data from KIT exon 11-mutant populations, often with lingering doubt about the efficacy in exon 9 cases. This study’s large sample size and robust statistical methodology, including the use of overlap weighting to mimic a randomized environment, offer a high degree of clinical confidence.
The observation that 400 mg/day may be sufficient is particularly impactful. In the advanced setting, the 800 mg dose is the standard of care for exon 9 mutations, but this dose is frequently associated with significant side effects, including severe fatigue, edema, and gastrointestinal distress, leading to poor adherence. If 400 mg/day provides equivalent adjuvant benefit, patients may experience better quality of life and higher rates of treatment completion.
However, the attenuation of RFS benefit over time warrants caution. As seen in other GIST trials, the protective effect of imatinib is most pronounced during the period of active treatment. This reinforces the current guideline-recommended duration of at least three years for high-risk patients and raises questions about whether even longer durations might be beneficial for certain molecular subsets.
Conclusion
This international cohort study clarifies the management of KIT exon 9-mutant GIST, confirming that adjuvant imatinib is independently associated with delayed recurrence and improved overall survival. These findings solidify the role of imatinib as the standard adjuvant care for this patient population. While the study suggests that a 400 mg/day dose is adequate, prospective randomized trials remain necessary to definitively establish the optimal dosing and the ideal duration of therapy to prevent late recurrences. For now, clinicians should prioritize genomic testing to identify exon 9 mutations and ensure these patients receive appropriate adjuvant therapy following surgery.
Funding and ClinicalTrials.gov
This research was supported by various international grants and institutional funds from participating referral centers. No specific ClinicalTrials.gov identifier is associated with this retrospective cohort study, though many participating centers contribute to the Life Raft Group database and ongoing prospective GIST registries.
References
1. Napolitano A, Joensuu H, Rothschild S, et al. Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations. JAMA Oncology. 2026. doi:10.1001/jamaoncol.2025.XXXX.
2. Joensuu H, Eriksson M, Hall KS, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265-1272.
3. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23(24):5795-5804.
4. Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33.
